Scarica l'app Stockscreener
76.99
1.69%
1.28
Dopo l'orario di chiusura:
77.20
0.21
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics (NKTR) Is Up 12.1% After REZPEG Data And Lawsuits CollideHas The Bull Case Changed? - Yahoo Finance
Do Rezpegaldesleukin Lawsuits Reframe Nektar Therapeutics' (NKTR) Core Risk Narrative Around Trial Integrity? - simplywall.st
NKTR PE Ratio & Valuation, Is NKTR Overvalued - Intellectia AI
NKTR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
Nektar Therapeutics at TD Cowen Conference: Immunology Focus - Investing.com
Class Actions Challenge Nektar Trial Disclosures And Investor Confidence Narrative - Sahm
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline - TipRanks
Assessing Nektar Therapeutics (NKTR) Valuation After A Sharp Multi‑Month Share Price Run - Sahm
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics ... - bdtonline.com
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
Nektar Therapeutics (NASDAQ:NKTR) Hits New 52-Week HighHere's Why - MarketBeat
Oppenheimer reiterates Nektar stock rating on alopecia data - Investing.com
Oppenheimer on Nektar Therapeutics (NKTR): 'meaningful opportunities for biologics in AA' - StreetInsider
Why Nektar Therapeutics Stock Is Surging Higher Today - TipRanks
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com
NEKTAR THERAPEUTICS NEKTAR THER (0UNL.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Nektar Therapeutics Bets Big on Respag Phase 3 - TipRanks
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Caledonian Record
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Nektar Therapeutics Shareholders Urged to Seek Compensation for Losses - National Today
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact ... - Caledonian Record
NKTR Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Nektar Showcases Rezpegaldesleukin Data As Phase 3 And Valuation Loom - simplywall.st
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Secu - GuruFocus
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
REZOLVE-AD: Rezpegaldesleukin Shows Consistent Efficacy Across Atopic Dermatitis Severity, With Raj Chovatiya, MD, PhD - hcplive.com
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies - TipRanks
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therape - gurufocus.com
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Black Hills Pioneer
Nektar presents rezpegaldesleukin data at dermatology meeting By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
First in Class Rezpegaldesleukin: Favorable Safety, Durable Responses in Alopecia Areata, With David Rosmarin, MD - HCPLive
ROSEN, LEADING INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com
Nektar’s eczema drug also cut hair-loss scores in 36-week study - stocktitan.net
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting - Sahm
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2 Healthcare Stocks to Buy Before They Get Bought Out - AOL.com
NEKTAR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
NKTR Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Vanguard disaggregates holdings; reports 0 shares in Nektar (NKTR) - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):